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Abstract
Radioiodine therapy (RIT) is an integral component in the treatment of differentiated
thyroid cancer (DTC). Patients usually undergo RIT as initial therapy or later in the case
of recurrent or persistent disease. The most important requirement for a successful RIT
is the ability of metastases and thyroid (remnant) tissue to accumulate radioiodine. In
order to calculate the achievable absorbed radiation dose for a lesion, volume and iodine
kinetics in the lesion need to be determined. Pretherapeutic imaging and dosimetry with
124I PET provide the methodology to answer these questions.
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1. Introduction
Thyroid cancer  is  divided into  differentiated thyroid cancer  (DTC)  and undifferentiated
thyroid cancer. In contrast to the undifferentiated thyroid cancer, the vast majority of the
DTC accumulates iodine in the tumour cells. Utilizing this characteristic, DTC patients can
undergo radioiodine therapy (RIT). RIT of DTC patients provides a very effective therapy
with only minimal side effects using standard activities, which is established for more than
half a century. Patients are treated according to their tumour stage. Low-risk patients usually
undergo a single RIT with activities up to 4 GBq 131I. High-risk patients undergo at least one
or several RIT with higher activities [1, 2]. While performing RIT with high activities of 131I,
the organs at risk need specific attention. These are the bone marrow and the lung, especial‐
ly in case of multiple metastases. The amount of 131I activity and the number of RIT depend
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on the results of the first RIT: if metastases were detected in the posttherapeutic scan, further
RIT may be necessary for an effective treatment of metastases. Therefore, a pretherapeutic
diagnostic, which detects iodine avid metastases, is desirable. The same holds for the first
RIT for patients with a high likelihood for metastases. The pretherapeutic risk stratification
is one of the greatest challenges in treating DTC patients. Although the overall prognosis for
the  most  DTC  patients  is  excellent  [3],  unfortunately,  some  DTC  patients  suffer  from
recurrences or persistent disease. These patients have already undergone RIT. In cases of
recurrent or persistent disease, the cancer cells often show less up to none radioiodine uptake.
Patients with low or missing radioiodine uptake would not or would only slightly benefit
from an additional RIT [4]. Therefore, the knowledge of the localization and the radioio‐
dine uptake level of lesions have great influence on therapy decision and the amount of
therapeutic activity.
Pretherapeutic imaging of DTC patients can be performed with different radioiodine isotopes
and the corresponding imaging modalities. 131I as diagnostic isotope is used since decades.
Usually, activities up to 185 MBq 131I are administered [5]. Another radioiodine isotope for
pretherapeutic imaging is 123I, which is hardly used due to its lower imaging sensitivity and
higher costs [5]. Both isotopes can be visualized by planar scintigraphies with a gamma camera
or as 3D imaging with a single photon emission tomography (SPECT) camera. Compared to
positron emission tomography (PET), the spatial resolution of gamma cameras is lower.
However, radioiodine diagnostics using 131I prior to intended RIT is not advisable mainly for
two reasons. First, until today it is not possible to derive reliable lesion dosimetry data from
131I scans. Second, 131I imaging needs relative high activities resulting in high radiation doses.
It is well known, that this leads to a so called stunning and, thus, reduces the response of
subsequent RIT [6].
124I PET in combination with computed tomography (CT) overcomes both problems. It offers
optimal imaging to detect radioiodine uptake in tumour cells before patients undergo RIT,
while only low 124I activities are required compared to 131I imaging [7–11]. Stunning is unlikely
and was not reported yet [5]. In addition, pretherapeutic 124I diagnostic provides, in compari‐
son with 131I and 123I, a higher quantitative capacity to perform a reliable lesion dosimetry. This
enables a tailor-made RIT with optimized absorbed tumour doses and an 131I activity, which
is considered to be safe for the patient, based on the blood dosimetry.
2. Patient preparation, 124I application and PET(/CT) imaging
There are two important requirements for a successful performance of 124I PET(/CT) diagnostics
or RIT: First, all patients are put on a low iodine diet. This is important to increase the
radioiodine uptake of the tumour cells. After performing a CT scan with contrast agents
containing iodine, for example, the tumour cells are saturated with iodine and would show
only a low radioiodine uptake. Therefore, any iodine contamination has to be avoided to ensure
a good radioiodine uptake during diagnostic imaging or therapy. Second, the tumour cells
have to be stimulated to achieve a high radioiodine uptake. The increase of the thyroid
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stimulating hormone (TSH) can be reached on two ways: endogenous or exogenous stimula‐
tion. The endogenous stimulation is usually chosen after initial thyroidectomy. Patients have
to stay on hormone withdrawal for about 4 weeks, until the TSH serum concentration exceeds
30 mU/l [2, 5]. During this time, patients may experience hypothyroid symptoms such as
fatigue, listlessness, depression and concentration disorders. The other way is an exogenous
stimulation with recombinant human TSH (rhTSH). The rhTSH is administered via an
intramuscular injection two and one day before diagnostic imaging or treatment. The exoge‐
nous stimulation spares patients having the hypothyroid symptoms. Moreover, a lower blood
dose was reported in rhTSH stimulated patients [12, 13] compared to endogenous stimulation.
However, the equivalence of therapeutic efficiency concerning tumour elimination under
rhTSH stimulation is not proven.
124I is a positron emitting nuclide with a half-life of 4.2 days. Like many other positron emitting
nuclides, 124I is produced in a cyclotron. Under endogenous or exogenous TSH stimulation,
124I can be administered in two different ways: orally or intravenously. The amount of admin‐
istered 124I activities reported in the literature is between 25 MBq and 74 MBq [7, 14, 15].
In the time of combined PET/CT scanners, it is much easier to locate focal radioiodine uptake
for example in the neck [16]. The new scanner generation provides fast scans with an acquis‐
ition time of e.g. 15 min for a scan from thigh to head. Besides the scan parameters and the
scanner properties, the time point of scan is very important. In the beginning of 124I PET(/CT)
imaging, multiple scans were performed at 4, 24, 48, 72, and ≥96 h after 124I application. This
time and resource consuming approach has been optimized and the necessary scans could be
reduced to 2 time points: 24 and 96 h after 124I application [14]. The first scan 24 h after 124I
application enables the detection of focal pathological iodine uptake as correlate for metastases
or local relapse. This scan is sufficient for diagnostic purpose. The first and second scans are
mainly needed for lesion dosimetry to estimate the lesion absorbed (radiation) dose during
RIT (details see below). However, occasionally, weakly radioiodine accumulating metastases
only show uptake in the late scan.
3. 124I PET(/CT) in initial DTC staging
The RIT is crucial for an effective treatment of DTC [17, 18]. Patients with higher initial tumour
stage or advanced disease with lymph node or distant metastases routinely undergo RIT with
higher 131I activities or several RIT. The knowledge of metastases prior to first RIT would be
beneficial for therapy planning. If no metastases are present, lower activities of 131I would be
reasonable. Patients with many metastases, especially bone or pulmonary metastases, should
be treated carefully because of bone marrow toxicity and the risk of radiation-related pneu‐
monitis or lung fibrosis [19, 20].
Another advantage of pretherapeutic 124I PET is the re-staging and especially up-staging in
patients with suspect findings in sonography. Shortly before RIT (about three weeks after
thyroidectomy) patients should undergo sonography of the neck. If conspicuous lymph nodes
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are present, additional clarification is necessary to adapt therapy management. In this process,
124I PET offers the possibility to detect focal iodine uptake in case of lymph node metastases
and therapy activity of 131I can be adapted. If no radioiodine uptake was found in conspicuous
lymph nodes, it might be a reactive lymph node or a radioiodine negative lymph node
metastasis; both will not be affected by the RIT.
During the first RIT, there is usually focal radioiodine uptake in the thyroid bed in
accordance with thyroid remnant tissues. Other focal radioiodine uptake located beyond the
thyroid bed is suspicious for malignancy, for example in the neck is typical for lymph node
metastases.
4. 124I PET(/CT) in patients with persisting or recurrent thyroid cancer
In the clinical course of patients with DTC, some patients suffer from tumour persistence after
initial RIT or experience a relapse of DTC at a later stage. These patients mostly present an
elevated and/or increasing serum level of thyroglobulin. Sometimes new tissue in the thyroid
bed or suspect lymph nodes can be detected in sonography of the neck as a correlate. The most
preferable therapy option would be an additional RIT in these cases. Unfortunately, thyroid
cancer cells can dedifferentiate and partially or completely lose the ability to accumulate
iodine. These patients with the so-called radioiodine negative metastases do not or only
slightly profit from additional RIT. Other therapies such as surgery or external beam radio‐
therapy would be the therapy of choice in radioiodine negative metastases. But not all patients
are radioiodine negative in case of recurrent disease. Therefore, a selection must be performed
prior to futile RIT.
After initial RIT and thyroid remnant ablation, no pathological focal iodine uptake should be
visible. Therefore, every focal uptake, for example in the neck or lung, is highly suspect for
metastases or local relapse (except physiological uptake, e.g. in the salivary glands).
5. 124I PET/MRI
Within the last years, simultaneous PET/MRI (PET/magnetic resonance imaging) has been
successfully implemented into scientific and clinical imaging, demonstrating its excellent
diagnostic potential, mainly in oncologic imaging. Based on its excellent soft tissue contrast,
MRI is known to provide superior assessment of head and neck tumours and with the
increasing implementation of integrated whole-body PET/MR devices, combining the strength
of PET as well as morphological and functional MRI. In this assessment, it could be of great
advantage in the localization of focal iodine uptake. The first publication about simultaneous
124I PET/MRI showed promising results [21].
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6. 124I Dosimetry
The 124I dosimetry deals with the determination of tumour lesion dose per administered 131I
activity (LDpA) and the estimation of the so-called maximum tolerable activity (MTA) of 131I.
The LDpA can help in the decision process if an additional RIT is a promising approach. If a
prescribed lesion dose seems to be reachable, the RIT is combined with a significant chance of
cure [22–24]. Due to the heterogeneity of metastases of a patient, there may be a significant
spread of LDpA in the different metastases. In consequence, RIT might be helpful in some
metastases and the other metastases need to be treated by surgery or external beam radio‐
therapy.
The MTA derived from blood dosimetry is the 131I activity that results in 2 Gy blood dose,
which is used as a surrogate for the bone marrow dose. Blood doses below 2 Gy are expected
to be tolerable without relevant side effects [19]. Furthermore, it is possible to evaluate the risk
of radiation-related fibrosis in patients with or without disseminated lung metastases [19, 20].
The blood dosimetry is based on blood sample (BS) and whole-body counter (WC) measure‐
ments (see Figures 1-3).
Figure 1. 124I PET/CT in initial staging. A: axial PET. B: axial CT. C: axial PET/CT fusion. D: PET MIP (maximum inten‐
sity projection). 19-year-old female patient with a papillary pT2 pN1 DTC, 4 weeks after thyroidectomy. The arrows
mark a radioiodine positive lymph node metastasis dorsal of the right clavicle. Moreover, another radioiodine positive
lymph node metastasis right cervical, thyroid remnant tissue in the thyroid bed and a lobus pyramidalis are visible.
Figure 2. 124I PET/CT in recurrent DTC. A: axial PET. B: axial CT. C: axial PET/CT fusion. D: PET MIP. 22-year-old fe‐
male patient with a papillary pT4 pN1 DTC, 5 years after thyroidectomy and RIT with 10.0 GBq 131I. The arrows mark a
radioiodine positive lymph node metastasis in the jugulum left. Moreover, further radioiodine positive lymph node
metastases right cervical are visible on image D.
Figure 3. 124I PET/MRI of the neck in recurrent DTC. A: axial PET. B: axial T1-W TSE sequence after contrast agent. C:
axial PET/MR fusion. 71-year-old male patient with a follicular pT2 pN0 DTC, 8 years after thyroidectomy and RIT
with 6.0 GBq 131I. The arrows mark a lymph node metastasis right cervical.
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The lesion and blood dosimetry consists of measurements at different time points after
application of 124I to determine the iodine kinetics. The lesion dosimetry requires a minimum
of two PET(/CT) scans at 24 and ≥96 h after 124I application. The blood dosimetry by the EANM
dosimetry committee uses a comprehensive protocol with measurements over at least 4 days
[25], which was optimized and shortened by Jentzen et al. [26]. For the optimized blood
dosimetry protocols, patients are divided into the groups prior to first RIT and after first RIT.
Prior to initial RIT, more measurements are recommended due to the presence of thyroid
tissue. After the first RIT, only three time points are sufficient. In Figure 4, the required
measurements are visualized. Further details on the calculations of lesion and blood dosimetry
can be found in Jentzen et al. [14, 26] (see examples in Figures 5 and 6).
Figure 4. Flowchart of 124I lesion and blood dosimetry. BS: blood sample; WC: whole-body counter.
7. Examples
Figure 5. 124I PET/CT and 124I PET/MRI in initial staging. A: axial 124I PET/CT (after 24 h). B: axial 124I PET/CT (after
96 h). C: axial 124I PET/MRI (after 24 h). D: 124I PET MIP (after 24 h). E: Whole-body scan after RIT with 7.0 GBq 131I (after
8 days). 47-year-old female patient with a papillary thyroid carcinoma (pT3 pN1a), 4 weeks after thyroidectomy. The
arrows mark two lymph node metastases right cervical. On images D and E, cervical lymph node metastases and thy‐
roid remnant tissue are visible. The blood dosimetry revealed a MTA of 18 GBq 131I, until the blood dose of 2 Gy is
reached. The lesion dosimetry estimated a LDpA ranging from 12 to 120 Gy/GBq 131I.
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Figure 6. 124I PET/CT and 124I PET/MRI in restaging. A: axial 124I PET/CT (after 24 h). B: axial 124I PET/CT (after 96 h). C:
axial 124I PET/MRI (after 24 h). D: 124I PET MIP (after 24 h). 44-year-old male patient with a papillary thyroid carcinoma
(pT3 pN1b), 1 year after thyroidectomy and RIT with 6.0 GBq 131I. Thyroglobulin increased without correlate in sonog‐
raphy of the neck. Therefore, a 124I PET dosimetry was performed for restaging. The arrows mark one lymph node
metastases right cervical paratracheal. On image D stomach, gastrointestinal tract and urinary bladder are visible. The
blood dosimetry revealed a MTA of 37 GBq 131I, until the blood dose of 2 Gy is reached. The lesion dosimetry estimated
a LDpA of 14 Gy/GBq 131I.
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